Healthcare Industry News: Biostat
News Release - January 8, 2008
Quintiles Names Head of Strategic Research, Medical, Regulatory, and Safety ServicesRESEARCH TRIANGLE PARK, N.C., Jan. 8 (HSMN NewsFeed) -- Quintiles Transnational Corp. today announced the appointment of Dipti Amin, M.D., as Senior Vice President of Strategic Research and Safety Services (SRS) and Medical and Regulatory Services, effective immediately. She will report to Jeff Thomis, President, Global Clinical Development Services.
Most recently, Amin served as Senior Vice President, Global Medical Services, Regulatory Affairs and Medical Writing, and Strategic Drug Development Unit. A long-time Quintiles employee, Amin is an industry veteran with extensive experience in a variety of industry-related disciplines, including: drug development, clinical operations, Phase I, data management, Biostatistics, medical writing, pharmacovigilance and regulatory affairs.
"Combining SRS with Medical and Scientific Services and Regulatory Affairs under Dipti's leadership will enable us to have greater strategic expertise in this growing market and maintain our leadership position in the safety environment," Thomis said.
About Strategic Research and Safety Services
The Strategic Research and Safety Services unit has specialist expertise in conducting the full spectrum of late phase and safety studies and advises pharmaceutical customers on drug development with the goal of maximizing medical benefit and minimizing the risk of therapies for patients.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With about 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.qtrn.com.
Source: Quintiles Transnational
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.